Shares of Ford Motor Co. (NYSE:F) [Trend Analysis] runs in leading trade, it moving down -0.25% to traded at $11.96. The firm has price volatility of 1.67% for a week and 1.42% for a month. Its beta stands at 1.14 times. Auto giant, Ford Motor Co. (F) released on Tuesday that its sales in China, the world’s largest auto market, climbed 24 percent in the month of September. The new Ford Focus reached around 20,000 sales in September, up 43 percent year-over-year.
Changan Ford Automobile, Ford’s passenger car joint venture, saw around 85,000 vehicles sold in the month, up 25 percent. Jiangling Motors Corp., Ford’s commercial vehicle investment in China, sold over 23,000 vehicles, a 28 percent raise compared to previous year. So far this year, sales for Ford, Lincoln and its joint ventures in China have totaled around 880,000 vehicles, up 11 percent over previous year, boosted by expanded SUV lineup. Narrow down four to firm performance, its weekly performance was -4.17% and monthly performance was -3.39%. The stock price of F is moving down from its 20 days moving average with -1.40% and isolated negatively from 50 days moving average with -2.65%.
Shares of Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) moved down 1.33% in last trading session as A member of the Roche Holding (RHHBY), Genentech reported that U.S. FDA has agreed a supplemental Biologics License Application or sBLA and granted Previousity Review for Lucentis or ranibizumab injection for the treatment of myopic choroidal neovascularization or mCNV, a complication of severe near-sightedness that can lead to blindness.
Genentech The sBLA is based on results from the Phase III RADIANCE study that demonstrated treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy, the only treatment presently agreed by the FDA for mCNV.
The FDA grants a Previousity Review designation to applications for medicines that treat serious conditions and, if agreed, would provide a important improvement in safety or efficacy. If agreed, Lucentis would be the first FDA-agreed anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV.